Novartis logo
Novartis is reimagining medicine to improve and extend people's lives. As a leading global medicines company, Novartis uses innovative science and digital technologies to create transformative treatments in areas of great medical need. Novartis has three divisions — Innovative Medicines, Alcon and Sandoz — supported by functional organizations with global scale. R&D is at the core of the company and central to the Novartis strategy. Novartis products are available in 155 countries. There are more than 200 projects in its clinical pipeline

Companies’ need for new reporting mechanisms to better measure and communicate the value — beyond financial — that they create for their stakeholders is increasingly being recognized. As businesses around the globe respond to calls to demonstrate their contribution to inclusive long-term value creation for all of society, the CEO of Novartis is part of the Coalition for Inclusive Capitalism, a group of CEOs from more than 20 global companies that together represent more than US$20 trillion of assets under management. Through the Embankment Project for Inclusive Capitalism, the coalition will work on a proof of concept to encourage and measure long-term value creation.

Vas Narasimhan, CEO of Novartis said (at a World Economic Forum 2018 side event):

There is always this assumption from the public sector and civil society that private institutions like Novartis have the profit motive that overtakes their motive to help society. I would argue it is actually the opposite. The only reason we can deliver profits to the world, to our company, and to our shareholders is when we positively impact society.

Over the past three years, Novartis has developed, tested and applied a methodology for valuing the financial, environmental and social (FES) impacts its business activities have on society. The results are intended to reflect the company’s social value beyond financial performance, taking into account the benefits and costs to society in monetary terms. Its impact valuation is still evolving, with gaps in methodologies and data. However, the company believes it is important to share its experiences to date, and Novartis invites external partners and stakeholders to engage with it and advance this field of study. Novartis is part of the Impact Valuation Roundtable.

External partners have made technical papers available:

Valuing The Impact of Wages On Human Capital

https://www.valuingnature.ch/single-post/2018/07/20/V.2ALUINGTHE-IMPACT-OF-WAGES-ON-HUMAN-CAPITAL

The Environmental Impact of Novartis Along Global Supply Chains (Case Study)

http://www.wifor.com/tlfiles/wifor/PDFPublikationen/2018_envimpact-novartis-along-global-supply-chains.pdf

The Global Economic Impact of Novartis

http://www.wifor.com/tlfiles/wifor/PDFPublikationen/180914casestudynovartisglobaleconomicWifOR.pdf

The Social Impact of Novartis medicines: Two Case Studies from South Africa and Kenya

http://www.wifor.com/tlfiles/wifor/PDFPublikationen/180914casestudynovartissocialimpactzaandkenya_WifOR.pdf